Clinical trial
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407 is registered in ClinicalTrials.gov with Servier Bio-Innovation LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
- Lead sponsor
- Servier Bio-Innovation LLC
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 9, 2024
- Completion date
- November 26, 2030
- Enrollment
- 136 (estimated)
- Sites
- 115
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced or metastatic conventional chondrosarcoma with an idh1 mutation, untreated or previously treated with 1 systemic treatment regimen